Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
0 hedge funds and large institutions have $0 invested in Lipella Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
0.11% less ownership
Funds ownership: 0.11% → 0% (-0.11%)
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $7.13K → $0 (-$7.13K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.8K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$314 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$18 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| – | -$6.8K | -2,708 | Closed |
|
|
MCM
2
MAI Capital Management
Independence,
Ohio
| – | -$314 | -125 | Closed |
|
|
3
Bank of America
Charlotte,
North Carolina
| – | -$18 | -7 | Closed |
|
LIPO Hedge Fund Activity: Q2 2025 in Review
0 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q2 2025, worth a combined $0 — down 100% from $7.13K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LIPO and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $6.8K sold.
- 0 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q2 2025, down from 3 in Q1 2025.
- Funds reported $0 of Lipella Pharmaceuticals stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new Lipella Pharmaceuticals positions in Q2 2025 and 3 closed out, a net change of -3 holders.
- The largest Lipella Pharmaceuticals seller in Q2 2025 was Tower Research Capital (TRC), an estimated $6.8K sold.
Based on aggregated 13F filings for Q2 2025.